VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

BACKGROUND: Pulmonary Arterial Hypertension (PAH) remains a therapeutic challenge, and the search continues for more effective drugs and drug combinations. We recently reported that deletion of the vasoactive intestinal peptide (VIP) gene caused the spontaneous expression of a PH phenotype that was...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamidi, Sayyed A, Lin, Richard Z, Szema, Anthony M, Lyubsky, Sergey, Jiang, Ya Ping, Said, Sami I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/
https://www.ncbi.nlm.nih.gov/pubmed/22029879
http://dx.doi.org/10.1186/1465-9921-12-141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3210095/
https://www.ncbi.nlm.nih.gov/pubmed/22029879
http://dx.doi.org/10.1186/1465-9921-12-141

Ejemplares similares